Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Novartis CEO Backs Malaria Drug Against COVID-19

Also Testing Jakavi, Gilenya And Ilaris

Mar 30 2020

• By Kevin Grogan

Vas Narasimhan — Vas Narasimhan • Source: Novartis

Related Content

FDA's Emergency Use Authorization for Malaria Drugs Could Hinder Trials of Other COVID-19 Treatments

Mar 31 2020

Off-Label Promoter In Chief: President Trump Pushes COVID-19 Therapy

Mar 24 2020

Chloroquine Moves To Top of COVID-19 Clinical Trial List

Mar 20 2020

Coronavirus Update: More Companies Join Therapeutics Accelerator, FDA Delays AdCom For First NASH Drug

Mar 27 2020

Related Companies

Novartis AG

Bayer AG

Sanofi

Viatris Inc.

Teva Pharmaceutical Industries Ltd.

Bristol Myers Squibb Company

Eli Lilly and Company

GSK plc

Johnson & Johnson

Merck & Co., Inc.

Pfizer Inc.

Additional Topics

Coronavirus COVID-19 Clinical Trials Companies Research & Development C-Suite Speaks BioPharmaceutical

More from COVID-19

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window